Study on the Efficacy and Survival of Zoledronic Acid in Preventing Skeletal Related Events in Solid Tumors
Objective To investigate the efficacy of zoledronic acid(ZOL)for a prospective early intervention in solid tumor bone metastasis,skeletal related events(SREs),and the effects on non-metastatic,non-SREs time to progress survival(TTPS),and overall survival(OS).Methods A total of 165 patients who were enrolled in our hospital from January 2016 to December 2020 were randomly divided into observation group(55 patients)and control group(110 patients)by 1:2 method.The patients in the observation group were treated with ZOL to prevent bone metastasis at the end of treatment,while the patients in the control group were treated without ZOL and followed up regularly at the end of the same period.The incidence of bone metastasis and SREs in the two groups and their relationship with survival were observed.Results There were 3 cases(5.45％)of bone metastasis and 2 cases(3.64％)of SREs in the observation group,which were lower than 26 cases(23.85％)and 19 cases(17.43％)in the control group,the differences were statistically significant(P＜0.05).There was no difference in OS and median survival time(MST)between the two groups by Log-rank method.The 1-5-year TTPS and median progress survival tim(MPST)were 87％,62％,31％,13％,0 and 29.0 months(95％CI:25.371-32.629)in the observation group,and 78％,55％,27％,2％,0 and 26.0 months(95％CI 21.717-30.283)in the control group,the difference was statistically significant(x2=4.155,P=0.040).Conclusion For patients with solid tumors that have not yet developed bone metastases,early use of ZOL prophylaxis after the end of anti-tumor specialist treatment can reduce the incidence of bone metastases and SREs,and prolong TTPS.Therefore,the application of ZOL to prevent solid tumor bone metastasis and SREs is effective and beneficial to progression-free survival.
Solid tumorBone metastasisZoledronic acidSkeletal related eventsNon-SREs time to progress
国家科技期刊平台
NSTL
万方数据
维普
